Chemo Plus Immunotherapy for Metastatic Triple-Negative Breast Cancer

Fact Checked

SurvivorNet Fact Checking and Medical Review Standards:  

The SurvivorNet News Team creates high quality medical information that complies with our industry leading standards for factual accuracy and sourcing from leading experts at academic medical institutions. Every news article is thoroughly fact-checked by our physician collaborators. We vet each piece of work for factual integrity, impartiality, and clearly label any professional conflicts.

All SurvivorNet articles adhere to the following standards:

  1. All studies and research papers cited are from reputable academic medical institutions or peer-reviewed journals.
  2. When we use data, statistics, or quotes these references link to the original source.
  3. All content related to new treatments, drugs, procedures, and so on must clearly describe availability, side effects, treatment target (such as triple negative breast cancer)
  4. All medical information on SurvivorNet is sourced from respected medical professionals with verified medical credentials and links are provided to these sources.
  5. We strive to give the reader relevant background information and include, clearly-sourced contextual health information in all articles. Readers are clearly alerted to any conflicts of interest from a medical source or the authors of a cited study.
/ Updated August 11th, 2022

Chemo Plus Immunotherapy for Metastatic Triple-Negative Breast Cancer

NOW
PLAYING
Treatment for Early Stage Triple-Negative Breast Cancer
NOW
PLAYING
Treatment Options for Metastatic Triple Negative Breast Cancer
NOW
PLAYING
Breast Cancer Breakthrough: Immunotherapy Shows Major Boost in Survival Rates
NOW
PLAYING
Study Finds Genes Linked to High-Risk for Triple-Negative Breast Cancer
NOW
PLAYING
Immunotherapy and Triple Negative Breast Cancer
NOW
PLAYING
What is Triple Negative Breast Cancer?

Patient Pathfinder:

Clinical Trial Finder

Are you looking for other treatment options?
Right now there are ... breast cancer trials in the U.S. within 100 miles of

Enter your zip code and travel distance to explore trials in your area...

Later Stage Treatment: HER2- and HER2 Low-- Dramatic Change in Treatment Paradigm

SEE MORE   

  • Experts say HER2- metastatic breast cancer patients should go back to their doctors to see whether their cancer is actually HER2 Low
  • Some women previously classified as HER2- may now qualify for treatment with a new drug called Enhertu that can extend overall survival rates

Later Stage Treatment: HER2- and HER2 Low-- Dramatic Change in Treatment Paradigm

  • Experts say HER2- metastatic breast cancer patients should go back to their doctors to see whether their cancer is actually HER2 Low
  • Some women previously classified as HER2- may now qualify for treatment with a new drug called Enhertu that can extend overall survival rates
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.